Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 5Terminated 4Recruiting 3Unknown 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1Dermatologic 1

Conditions

Hodgkin Disease 8Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Sezary Syndrome 1Mesothelioma, Malignant 1Lymphomatoid Papulosis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × Brentuximab Vedotin × Clear all
NCT07624838 2026-06-03

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Recruiting
100 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03719105 2025-08-08

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

New York Medical College

Phase EARLY_PHASE1 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Leukemia, Large Granular Lymphocytic

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Yale University

Phase 2 Recruiting
32 enrolled
DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡